Literature DB >> 9886114

Effectiveness of Bacillus Calmette Guerin (BCG) vaccination in the prevention of childhood pulmonary tuberculosis: a case control study in Nagpur, India.

S P Zodpey1, S N Shrikhande, B R Maldhure, N D Vasudeo, S W Kulkarni.   

Abstract

A hospital-based, pair matched, case control study was carried out to estimate the effectiveness of BCG vaccination in the prevention of childhood pulmonary tuberculosis. The study included 126 incident cases of pulmonary tuberculosis (diagnosed by WHO criteria) below/equal the age of 12 years. Each case was pair matched with one control for age, sex, socio-economic status. Controls were selected from subjects attending study hospital for conditions other than tuberculosis and leprosy. The significant protective association between BCG and childhood pulmonary tuberculosis was observed (OR = 0.39, 95% CI = 0.22, 0.68). The overall vaccine effectiveness was 61% (95% CI = 32%, 78%). BCG was nonsignificantly more effective in underfives, among males and in upper-middle socioeconomic strata. The overall prevented fraction was estimated to be 47.53% (95% CI = 21.41%, 67.25%). Results of this study thus demonstrated a moderate effectiveness of BCG vaccination in prevention of childhood pulmonary tuberculosis in a Central India population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9886114

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  4 in total

1.  Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring.

Authors:  Janine Jason; Lennox K Archibald; Okey C Nwanyanwu; Peter N Kazembe; Julie A Chatt; Elizabeth Norton; Hamish Dobbie; William R Jarvis
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

2.  Safety and Immunogenicity of the Recombinant Mycobacterium bovis BCG Vaccine VPM1002 in HIV-Unexposed Newborn Infants in South Africa.

Authors:  André G Loxton; Julia K Knaul; Leander Grode; Andrea Gutschmidt; Christiane Meller; Bernd Eisele; Hilary Johnstone; Gian van der Spuy; Jeroen Maertzdorf; Stefan H E Kaufmann; Anneke C Hesseling; Gerhard Walzl; Mark F Cotton
Journal:  Clin Vaccine Immunol       Date:  2017-02-06

3.  Integrating Non-human Primate, Human, and Mathematical Studies to Determine the Influence of BCG Timing on H56 Vaccine Outcomes.

Authors:  Louis R Joslyn; Elsje Pienaar; Robert M DiFazio; Sara Suliman; Benjamin M Kagina; JoAnne L Flynn; Thomas J Scriba; Jennifer J Linderman; Denise E Kirschner
Journal:  Front Microbiol       Date:  2018-08-17       Impact factor: 5.640

Review 4.  It Takes a Village: The Multifaceted Immune Response to Mycobacterium tuberculosis Infection and Vaccine-Induced Immunity.

Authors:  Sasha E Larsen; Brittany D Williams; Maham Rais; Rhea N Coler; Susan L Baldwin
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.